A 9-0 Supreme Court ruling said Hikma’s generic Vascepa did not infringe Amarin patents, reversing a lower-court decision that had revived Amarin’s lawsuit.
Justice Ketanji Brown Jackson wrote that Amarin showed only a “sheer possibility” of induced infringement, not that Hikma actively encouraged doctors to use the drug for patented indications.
Hikma’s generic was FDA-approved only for severe hypertriglyceridemia with a skinny label omitting Amarin’s still-patented use in less-severe cases; the court said calling it equivalent to Vascepa was standard industry practice.
The decision is seen as strengthening the skinny-label pathway for generics, which Hikma and the Trump administration argued helps preserve lower-cost competition and avoid higher drug prices.
For Amarin, the stakes are high: Vascepa is its only product and generated $213.6 million in 2025 revenue, though the company said it is evaluating next steps.
Will drug companies stop researching new uses for old medicines after this ruling?
What is the next legal battleground for brand-name and generic drug companies?
2026 Supreme Court Decision Clarifies Induced Infringement Standard for Skinny Labels in Generic Pharmaceuticals
Overview
The Supreme Court's unanimous decision in June 2026 clarified the rules for generic drug makers using 'skinny labels.' The case began when Amarin sued Hikma, claiming that Hikma’s marketing and labeling encouraged doctors to prescribe its generic Vascepa for uses still protected by Amarin’s patents. The Federal Circuit had agreed with Amarin, saying Hikma’s references to 'generic Vascepa' could mislead doctors. However, the Supreme Court ruled that simply calling a product a generic version is not enough to prove inducement of patent infringement. This decision gives generic companies clearer guidance and helps balance affordable drug access with patent rights.